OpGen Inc  

(Public, NASDAQ:OPGN)   Watch this stock  
Find more results for OPGN
1.36
-0.05 (-3.55%)
Jan 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.23 - 1.38
52 week 0.87 - 4.65
Open 1.36
Vol / Avg. 954,347.00/2.31M
Mkt cap 28.49M
P/E     -
Div/yield     -
EPS -1.30
Shares 21.72M
Beta     -
Inst. own 44%
Mar 28, 2017
Q4 2016 OpGen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Oct 24, 2016
Q3 2016 OpGen Inc Earnings Call
Oct 24, 2016
Q3 2016 OpGen Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -638.14% -549.51%
Operating margin -632.60% -476.90%
EBITD margin - -457.12%
Return on average assets -166.00% -211.46%
Return on average equity -347.32% -
CDP Score - -

Address

708 Quince Orchard Rd Ste 205
GAITHERSBURG, MD 20878-1793
United States - Map
+1-240-8131260 (Phone)
+1-301-8699684 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

Officers and directors

Evan Jones Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Timothy C. Dec Interim Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
C. Eric Winzer Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
G. Terrance Walker Ph.D. Senior Vice President - Research and Development
Age: 55
Bio & Compensation  - Reuters
Vadim Sapiro Chief Information Officer
Age: 43
Bio & Compensation  - Reuters
David Hoekzema Vice President - Business Development and Operations
Age: 52
Bio & Compensation  - Reuters
Robert McG. Lilley Chief Commercial Officer
Age: 69
Bio & Compensation  - Reuters
Harry J. D'Andrea Director
Age: 58
Bio & Compensation  - Reuters
Timothy J.R. Harris Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
David M. Rubin Ph.D. Director
Age: 49
Bio & Compensation  - Reuters